NASDAQ:BLFS

BioLife Solutions Stock Forecast, Price & News

$39.60
+0.97 (+2.51 %)
(As of 06/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$37.72
$40.06
50-Day Range
$29.51
$39.60
52-Week Range
$15.05
$47.97
Volume382,769 shs
Average Volume290,910 shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.45
30 days | 90 days | 365 days | Advanced Chart
Receive BLFS News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.


BioLife Solutions logo

About BioLife Solutions

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.96 out of 5 stars

Medical Sector

98th out of 2,100 stocks

Electromedical Equipment Industry

3rd out of 61 stocks

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BioLife Solutions (NASDAQ:BLFS) Frequently Asked Questions

Is BioLife Solutions a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BioLife Solutions stock.
View analyst ratings for BioLife Solutions
or view top-rated stocks.

What stocks does MarketBeat like better than BioLife Solutions?

Wall Street analysts have given BioLife Solutions a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioLife Solutions wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioLife Solutions' next earnings date?

BioLife Solutions is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for BioLife Solutions
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) announced its quarterly earnings results on Wednesday, May, 12th. The medical equipment provider reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.02. The medical equipment provider earned $16.85 million during the quarter, compared to analysts' expectations of $15.60 million. BioLife Solutions had a negative trailing twelve-month return on equity of 0.35% and a negative net margin of 39.34%.
View BioLife Solutions' earnings history
.

How has BioLife Solutions' stock price been impacted by Coronavirus?

BioLife Solutions' stock was trading at $12.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLFS shares have increased by 223.3% and is now trading at $39.60.
View which stocks have been most impacted by COVID-19
.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided EPS guidance of $- for the period. The company issued revenue guidance of $106 million-115 million, compared to the consensus revenue estimate of $105.65 million.

What price target have analysts set for BLFS?

9 Wall Street analysts have issued twelve-month target prices for BioLife Solutions' stock. Their forecasts range from $33.00 to $61.00. On average, they anticipate BioLife Solutions' stock price to reach $50.38 in the next twelve months. This suggests a possible upside of 27.2% from the stock's current price.
View analysts' price targets for BioLife Solutions
or view top-rated stocks among Wall Street analysts.

Who are BioLife Solutions' key executives?

BioLife Solutions' management team includes the following people:
  • Mr. Michael P. Rice, Pres, CEO & Director (Age 58, Pay $514.71k)
  • Mr. Roderick de Greef, CFO, COO & Sec. (Age 61, Pay $390.89k)
  • Dr. Aby J. Mathew, Chairman of Scientific Advisory Board, Exec. VP & Chief Scientific Officer (Age 49, Pay $407.64k)
  • Mr. Todd Berard, Chief Marketing Officer (Age 52, Pay $286.49k)
  • Ms. Karen Foster, Chief Quality Officer (Age 61, Pay $345.73k)
  • Ms. Sarah Aebersold J.D., VP of Global HR (Age 45)
  • Mr. Marcus Schulz, Chief Revenue Officer (Age 42)

What is Mike Rice's approval rating as BioLife Solutions' CEO?

5 employees have rated BioLife Solutions CEO Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among BioLife Solutions' employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of BioLife Solutions' key competitors?

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include (CGC), Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.89%), Wasatch Advisors Inc. (3.36%), Geneva Capital Management LLC (3.09%), Ameriprise Financial Inc. (2.72%), Russell Investments Group Ltd. (1.93%) and TimesSquare Capital Management LLC (1.45%). Company insiders that own BioLife Solutions stock include Aby J Mathew, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Karen A Foster, Marcus Schulz, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger.
View institutional ownership trends for BioLife Solutions
.

Which major investors are selling BioLife Solutions stock?

BLFS stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Wasatch Advisors Inc., Russell Investments Group Ltd., Tower House Partners LLP, Sentinel Pension Advisors Inc., Jennison Associates LLC, D. E. Shaw & Co. Inc., and Calamos Advisors LLC. Company insiders that have sold BioLife Solutions company stock in the last year include Aby J Mathew, Andrew G Hinson, Greef Roderick De, Joseph C Schick, Karen A Foster, Marcus Schulz, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard, and Walter Villiger.
View insider buying and selling activity for BioLife Solutions
or view top insider-selling stocks.

Which major investors are buying BioLife Solutions stock?

BLFS stock was acquired by a variety of institutional investors in the last quarter, including Geneva Capital Management LLC, Palisade Capital Management LLC NJ, Millennium Management LLC, RMB Capital Management LLC, Premier Fund Managers Ltd, Victory Capital Management Inc., JPMorgan Chase & Co., and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp.
View insider buying and selling activity for BioLife Solutions
or or view top insider-buying stocks.

How do I buy shares of BioLife Solutions?

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $39.60.

How much money does BioLife Solutions make?

BioLife Solutions has a market capitalization of $1.60 billion and generates $48.09 million in revenue each year. The medical equipment provider earns $2.67 million in net income (profit) each year or $0.01 on an earnings per share basis.

How many employees does BioLife Solutions have?

BioLife Solutions employs 193 workers across the globe.

What is BioLife Solutions' official website?

The official website for BioLife Solutions is www.biolifesolutions.com.

Where are BioLife Solutions' headquarters?

BioLife Solutions is headquartered at 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at rdeg[email protected]


This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.